524735

Hikal Limited announced the availability of the audio recording of its earnings group conference call for the quarter and financial year ended March 31, 2026, held on May 27, 2026, on the company's website.

Consolidated Revenue ₹519 Cr vs ₹552 Cr (▼6% YoY), EBITDA ₹105 Cr vs ₹123 Cr (▼15% YoY), PAT ₹14 Cr vs ₹50 Cr (▼72% YoY). EBITDA Margin 20% vs 22% (▼200bps).

Standalone Operating Revenue ₹5,194Mn vs ₹5,524Mn (▼6.0% YoY), EBITDA ₹1,086Mn vs ₹1,235Mn (▼12.1% YoY), PAT ₹146Mn vs ₹503Mn (▼71.0% YoY). EBITDA Margin 20.9% vs 22.4% (▼145bps). The Board recommended a final dividend of ₹0.40 per share, bringing the total FY25-26 dividend to ₹0.60 per share. Key negative updates include an ongoing Supreme Court case regarding alleged environmental non-compliance, past revenue recognition irregularities leading to an external fact-finding review, a significant impairment charge of ₹471Mn due to repurposing a manufacturing plant, and a USFDA warning letter impacting the Pharma Segment's sales.

Hikal announced the appointment of Mr. Ravi Khadabadi as President-Crop Protection & Specialty Chemicals, effective May 27, 2026. The company also provided an update on previous irregularities related to the timing of revenue recognition. An external review confirmed the irregularities were limited to the preponement of underlying genuine sales, with no impact on current/previous periods. Corrective actions have been implemented, and the employees involved have been relieved from services.

Standalone Operating Revenue ₹5,194Mn vs ₹5,524Mn (▼6.0% YoY), EBITDA ₹1,056Mn vs ₹1,235Mn (▼14.5% YoY), PAT ₹146Mn vs ₹503Mn (▼71.0% YoY). EBITDA Margin 20.3% vs 22.4% (▼210bps).

Hikal Ltd. announced the appointment of Mr. Ravi Khadabadi as President - Crop Protection & Specialty Chemicals, effective May 27, 2026. Separately, the company provided an update on earlier disclosed irregularities concerning revenue recognition timing from September 30, 2025. An external review confirmed irregularities were limited to the preponement of genuine sales. Corrective actions were taken, involved employees relieved, and management concluded no impact on current/previous periods.

Hikal Limited appointed Mr. Ravi Khadabadi as President - Crop Protection & Specialty Chemicals, effective May 27, 2026. The company also provided an update on earlier disclosed irregularities regarding revenue recognition timing, where employees had preponed genuine sales. Corrective actions were taken, including relieving involved employees, and an external review confirmed no financial impact on current/previous periods.

Standalone Revenue ₹519.4Cr vs ₹552.4Cr (▼6.0% YoY), EBITDA ₹105.6Cr vs ₹123.5Cr (▼14.5% YoY), PAT ₹14.6Cr vs ₹50.3Cr (▼71.0% YoY). EBITDA Margin 20.3% vs 22.4% (▼210bps). The Board also recommended a final dividend of ₹0.40 per share, making the total dividend for FY26 ₹0.60 per share, significantly lower than the previous year's ₹1.40 per share. The company noted ongoing investigations related to alleged environmental non-compliance and an USFDA warning letter impacting Pharma sales.

Consolidated Revenue ₹519.4 Cr vs ₹552.4 Cr (▼6.0% YoY), EBITDA ₹105.4 Cr vs ₹123.4 Cr (▼14.6% YoY), PAT ₹14.4 Cr vs ₹50.2 Cr (▼71.3% YoY). EBITDA Margin 20.3% vs 22.3% (▼200bps). The Board also recommended a final dividend of 20% (₹0.40 per share), bringing the total dividend for FY26 to 30% (₹0.60 per share), and appointed Mr. Sandip Parikh as an Independent Director.

Hikal Limited announced the rescheduling of its Q4 & FY26 post-results conference call. Originally set for May 27, 2026, at 4:30 PM (IST), it will now be held on the same day at 5:30 PM (IST) to discuss the company's financial and operational performance.